CompaniesWindMIL Therapeutics

WindMIL Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (3)
View all

Total Trials

3

As Lead Sponsor

1

As Collaborator

2

Total Enrollment

25

By Phase

EARLY_PHASE1: 1NA: 1PHASE2: 1

By Status

TERMINATED: 2WITHDRAWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
Today
NCT04069936
NCT04677361
Hover over trial bars to see details

Recent Trials

NCT04677361Collaborator
Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab
EARLY_PHASE1Withdrawn
Started: Oct 31, 2021 · Completed: Oct 31, 2024
NCT04341740Collaborator
Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma
NATerminated
6 participants
Started: Jul 22, 2020 · Completed: Apr 9, 2021
NCT04069936Lead Sponsor
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
PHASE2Terminated
19 participants
Started: Oct 15, 2019 · Completed: Nov 30, 2021
Funding History (3)
D
Feb 5, 2021
Filing
D
Jun 15, 2018
Filing
D
Apr 7, 2016
Filing